COMPARING COST-UTILITY OF DMARDs IN AUTOANTIBODY-NEGATIVE RHEUMATOID ARTHRITIS PATIENTS.

To evaluate the 1-year cost-effectiveness between three different initial treatment strategies in autoantibody-negative rheumatoid arthritis(RA-) patients, according to 2010 criteria.For this analysis we selected all RA- patients within the intermediate probability stratum of the tREACH trial. The tREACH had a treat-to-target approach, aiming for low disease activity(DAS<2.4) and treatment adjustments could occur every 3 months. Initial treatment strategies consisted of methotrexate 25mg/week(iMTX), hydroxychloroquine 400mg/day(iHCQ) or an oral glucocorticoids tapering scheme without DMARDs(iGCs). Data on Quality adjusted life-years(QALYs), measured with the EQ-5D-3L, healthcare and productivity costs were used.Average QALYs(sd), for iMTX, iHCQ and iGCs were respectively 0.71(0.14), 0.73(0.14) and 0.71(0.15). The average total costs(sd) for iMTX, iHCQ and iGCs were respectively €10.832(14.763), €11.208 (12.801) and €10.502(11.973). Healthcare costs were mainly determined by biological costs, which were significantly lower in the iHCQ group compared to iGCs(p


View the full article @ Rheumatology (Oxford, England)


Get PDF with LibKey
Authors: Luurssen-Masurel Nathalie, Mulligen van Elise, Weel Angelique Elisabeth Adriana Maria, Hazes Johanna Maria Wilhelmina, Jong Pascal Hendrik Pieter de, tREACH group investigators